# PRESTO (NCT04115007)

> Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

No report yet. It can be ordered.

- Indication: oligometastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04115007
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Oligometastatic Hormone Sensitive Prostate Cancer
- Interventions: Stereotactic Body Radiotherapy (SBRT) + Standard of care; Standard of care
- Enrollment: 550
- Primary outcome: Castration-resistant prostate cancer free survival

## Topics in the commentary so far

Topics in 40 sources so far: early toxicity with metastasis-directed therapy; early efficacy assessments with metastasis-directed therapy.

_From 13 authors, 3 of them verified clinicians. Automated from the 40 newest of 160 indexed sources (Oct 2025 – Oct 2026). Each topic is raised in at least two. Not an Erudio report: no source links. Not medical advice._

## Indexed commentary on PRESTO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 78 posts on X
- 42 YouTube videos
- 40 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=presto-nct04115007

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04115007", "email": "<work email>"}; the inbox owner confirms by the emailed link.